MARKET

ADGI

ADGI

Adagio Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.750
-0.230
-5.78%
Pre Market: 3.870 +0.12 +3.20% 04:11 08/12 EDT
OPEN
3.990
PREV CLOSE
3.980
HIGH
4.020
LOW
3.705
VOLUME
3
TURNOVER
--
52 WEEK HIGH
78.82
52 WEEK LOW
2.410
MARKET CAP
411.53M
P/E (TTM)
-1.2181
1D
5D
1M
3M
1Y
5Y
Billionaire Dan Loeb is Adding These 9 Stocks in his Portfolio
In this article, we will discuss the 9 stocks billionaire Dan Loeb is adding to his portfolio. If you want to skip reading about Dan Loeb’s investment philosophy and his hedge fund’s performance, you can go directly to Billionaire Dan Loeb is Adding These ...
Insider Monkey · 07/22 13:11
ARWR, TRIP and CARA among after hour movers
Gainers: Burning Rock Biotech (BNR) +4%. TripAdv...
Seekingalpha · 07/08 21:17
The Petri Dish: FDA to fast-track Biogen's next Alzheimer's drug
The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory route used by the companies for Aduhelm.
American City Business Journals · 07/07 09:30
Is Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 07/06 16:44
Sector Update: Health Care
MT Newswires · 07/05 13:38
Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign
AUSTIN, Texas, July 05, 2022--Mithril Capital Management LLC ("Mithril"), a founding investor in and the leader of a consortium of investors that represented approximately 49% of the outstanding shares of Adagio Therapeutics, Inc. (Nasdaq: ADGI) ("Adagio")...
Business Wire · 07/05 12:00
Adagio names David Hering as permanent CEO and Director
Adagio Therapeutics (NASDAQ:ADGI) has <a href="https://seeking...
Seekingalpha · 07/05 11:34
Adagio Therapeutics Appoints David Hering Permanent CEO and Director
MT Newswires · 07/05 09:26
More
No Data
Learn about the latest financial forecast of ADGI. Analyze the recent business situations of Adagio Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
75.00%Hold
25.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADGI stock price target is 3.833 with a high estimate of 5.00 and a low estimate of 3.000.
High5.00
Average3.833
Low3.000
Current 3.750
EPS
Actual
Estimate
-0.82-0.62-0.41-0.21
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 76
Institutional Holdings: 53.84M
% Owned: 49.06%
Shares Outstanding: 109.74M
TypeInstitutionsShares
Increased
32
9.89M
New
18
2.20M
Decreased
14
2.44M
Sold Out
22
10.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.11%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Chairman/Director
Marc Elia
Chief Executive Officer/Director
David Hering
Chief Financial Officer
Jane Henderson
Chief Technology Officer
Rebecca Dabora
Other
Elham Hershberger
Secretary
Jill Andersen
Director
Tamsin Berry
Director
Terrance McGuire
Director
Clive Meanwell
Independent Director
Tomas Heyman
Independent Director
Redonda Miller
Independent Director
Michael Wyzga
No Data
No Data
About ADGI
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The Company has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.

Webull offers kinds of Adagio Therapeutics Inc stock information, including NASDAQ:ADGI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADGI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADGI stock methods without spending real money on the virtual paper trading platform.